Financial Lp Hrt Sells 3,183 Shares of Clearmind Medicine (NASDAQ:CMND) Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 3,183 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $3.32, for a total transaction of $10,567.56. Following the sale, the insider owned 103,492 shares in the company, valued at approximately $343,593.44. The trade was a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 16th, Financial Lp Hrt sold 22,139 shares of Clearmind Medicine stock. The shares were sold at an average price of $3.31, for a total transaction of $73,280.09.
• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.36, for a total transaction of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The stock was sold at an average price of $0.12, for a total value of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt bought 2,159,052 shares of Clearmind Medicine stock. The shares were purchased at an average price of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Price Performance

CMND opened at $3.07 on Friday. The company has a market capitalization of $3.13 million, a price-to-earnings ratio of -0.02 and a beta of 0.64. The business’s 50-day moving average price is $5.56 and its two-hundred day moving average price is $14.82. Clearmind Medicine Inc. has a 1 year low of $2.10 and a 1 year high of $524.00.

Clearmind Medicine (NASDAQ:CMND) last posted its quarterly earnings data on Monday, June 15th. The company reported ($6.78) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Clearmind Medicine to a “sell” rating in a research report on Saturday, May 23rd.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.